Virbac S.A (VIRP) | Stock Overview & Key Data

What is VIRP's 52-week high and low?

In the last 52 weeks, Virbac S.A reached a high of €389.50 (on April 17, 2026) and a low of €296.00 (on N/A).

What is the market cap and P/E ratio for VIRP?

Curious about Virbac S.A's size and valuation? Its market capitalization stands at 3.17B. When it comes to valuation, the P/E ratio (trailing twelve months) is 21.00, and the forward P/E (looking ahead) is 16.46.

Does VIRP pay dividends? If so, what's the yield?

Yes, Virbac S.A is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.80%, and the company has paid an average of €1.30 per share annually over the past 3 years.

Who are Virbac S.A's main competitors or similar companies to consider before investing?

When looking at Virbac S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Sanofi SAN	N/A	Healthcare	Drug Manufacturers - General	-6.59%	-6.59%
TheraVet S.A ALVET	N/A	Healthcare	Biotechnology	-89.74%	-98.11%
EssilorLuxottica EL	88.12B	Healthcare	Medical Instruments & Supplies	-6.21%	-6.21%
Sartorius Stedim DIM	15.79B	Healthcare	Medical Instruments & Supplies	6.42%	6.42%
Ipsen S.A IPN	13.43B	Healthcare	Drug Manufacturers - Specialty & Generic	52.76%	40.77%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Virbac S.A.? (e.g., ROE, Debt/Equity)

To get a sense of Virbac S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 13.88%, the Debt to Equity ratio from the most recent quarter is 25.75, and its Gross Profit Margin stands at N/A.

What is the recent revenue and earnings growth for VIRP?

Looking at Virbac S.A's growth, its revenue over the trailing twelve months (TTM) was €1B. Compared to the same quarter last year (YoY), quarterly revenue grew by 4.60%, and quarterly earnings saw a YoY growth of 35.30%.

How much of VIRP stock is held by insiders and institutions?

Wondering who owns Virbac S.A stock? Company insiders (like executives and directors) hold about 50.81% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 25.01%.

For more common questions about our data, please visit our About Data page.